t
| Date | 13 Jul 2023 |
| Time | 09:14:48 |
| Category | Miscellaneous |
| ID | 9278F |
13 July 2023
Scancell Holdings plc
("Scancell" or the "Company")
Extension of exercise period for CEO share options
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that the exercise period for 3.85 million share options awarded to Lindy Durrant, Chief Executive Officer of the Company, on 30 July 2020 will be extended from 30 July 2023 to 30 July 2026.
These options have an exercise price of 4.5 pence each. All other conditions of the award remain the same.
The extension of the expiry date for the share options amounts to a related party transaction within the meaning of the AIM Rules for Companies. The Directors who are independent of the related party transaction (being all the Directors of the Company other than Lindy Durrant) having consulted with Stifel, the Company's nominated adviser, consider this proposed extension of the expiry date to be fair and reasonable insofar as the shareholders of the Company are concerned.
|
For further information, please contact: |
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Dr Jean-Michel Cosséry, Non-Executive Chairman |
|
|
Professor Lindy Durrant, CEO |
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7710 7600 |
|
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) |
|
|
Nick Adams/Nick Harland (Corporate Broking) |
|
|
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) |
+44 (0) 20 7886 2500 |
|
Freddy Crossley/Emma Earl (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
|
|
|
Consilium Strategic Communications |
+44 (0) 20 3709 5700 |
|
Mary-Jane Elliott/Matthew Neal/Chris Welsh |
|
|
|
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/